Myelodysplastic syndromes

Common Name(s)

Myelodysplastic syndromes, MYELODYSPLASTIC SYNDROME

Myelodysplastic syndromes (MDS) are a rare group of blood disorders characterized by abnormal development of blood cells within the bone marrow. Individuals with MDS have abnormally low blood cell levels (low blood counts). Signs and symptoms associated with MDS include dizziness, fatigue, weakness, shortness of breath, bruising and bleeding, frequent infections, and headaches. In some cases, MDS may progress to bone marrow failure or an acute leukemia. The exact cause of MDS is unknown. It sometimes runs in families, but no disease-causing gene has been identified. Treatment depends on the affected individual's age, general health, and type of MDS and may include red cell and/or platelet transfusions and antibiotics.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Myelodysplastic syndromes" for support, advocacy or research.

Logo
Aplastic Anemia & MDS International Foundation

The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH), and related bone marrow failure diseases. AA&MDSIF provides answers, support and hope to thousands of patients and their families around the world.

http://www.aamds.org/

Last Updated: 29 Apr 2014

View Details
National Bone Marrow Transplant Link

The mission of the National Bone Marrow Transplant Link is to help patients, caregivers, and families cope with the social and emotional challenges of bone marrow/stem cell transplant from diagnosis through survivorship by providing vital information and personalized support services.

http://www.nbmtlink.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Myelodysplastic syndromes" returned 716 free, full-text research articles on human participants. First 3 results:

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
 

Author(s): Aziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, John Barnard, Najla H Al Ali, Gail J Roboz, David P Steensma, Amy E DeZern, Cassie Zimmerman, Elias J Jabbour, Katrina Zell, Alan F List, Hagop M Kantarjian, Jaroslaw P Maciejewski, Rami S Komrokji,

Journal: Leuk. Res.. 2016 Feb;41():43-7.

 

Treatment with hypomethylating agents (HMAs) improves overall survival (OS) in patients who achieve a response of stable disease (SD) or better (complete remission [CR], partial remission [PR], or hematologic improvement [HI]). It is not well established if patients who achieve SD ...

Last Updated: 3 Feb 2016

Go To URL
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
 

Author(s): Virginie Chesnais, Aline Renneville, Andrea Toma, Jérôme Lambert, Marie Passet, Florent Dumont, Sylvie Chevret, Julie Lejeune, Anna Raimbault, Aspasia Stamatoullas, Christian Rose, Odile Beyne-Rauzy, Jacques Delaunay, Eric Solary, Pierre Fenaux, François Dreyfus, Claude Preudhomme, Olivier Kosmider, Michaela Fontenay,

Journal: Blood. 2016 Feb;127(6):749-60.

 

Non-del(5q) transfusion-dependent low/intermediate-1 myelodysplastic syndrome (MDS) patients achieve an erythroid response with lenalidomide in 25% of cases. Addition of an erythropoiesis-stimulating agent could improve response rate. The impact of recurrent somatic mutations identified ...

Last Updated: 12 Feb 2016

Go To URL
Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.
 

Author(s): Feng Xu, Ling-Yun Wu, Chun-Kang Chang, Qi He, Zheng Zhang, Li Liu, Wen-Hui Shi, Juan Guo, Yang Zhu, You-Shan Zhao, Shu-Cheng Gu, Cheng-Ming Fei, Dong Wu, Li-Yu Zhou, Ji-Ying Su, Lu-Xi Song, Chao Xiao, Xiao Li

Journal:

 

The progressive mechanism underlying myelodysplastic syndrome remains unknown. Here we identify ROBO1 and ROBO2 as novel progression-related somatic mutations using whole-exome and targeted sequencing in 6 of 16 (37.5%) paired MDS patients with disease progression. Further deep sequencing ...

Last Updated: 26 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Myelodysplastic syndromes" returned 131 free, full-text review articles on human participants. First 3 results:

Deconstructing innate immune signaling in myelodysplastic syndromes.
 

Author(s): Melinda E Varney, Katelyn Melgar, Madeline Niederkorn, Molly A Smith, Laura Barreyro, Daniel T Starczynowski

Journal: Exp. Hematol.. 2015 Aug;43(8):587-98.

 

Overexpression of immune-related genes is widely reported in myelodysplastic syndromes (MDSs), and chronic immune stimulation increases the risk for developing MDS. Aberrant innate immune activation, such as that caused by increased toll-like receptor (TLR) signaling, in MDS can contribute ...

Last Updated: 17 Aug 2015

Go To URL
Incidence and Burden of the Myelodysplastic Syndromes.
 

Author(s): Christopher R Cogle

Journal: Curr Hematol Malig Rep. 2015 Sep;10(3):272-81.

 

Since 2001, cases of myelodysplastic syndromes (MDSs) have been tracked by cancer registries. Examining registry data in the USA, the reported age-adjusted incidence of MDS per 100,000 was 3.3 per year for 2001-2003 and 4.9 per year for 2007-2011, with increases likely a result of ...

Last Updated: 31 Aug 2015

Go To URL
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?
 

Author(s): Rafael Bejar

Journal: Curr Hematol Malig Rep. 2015 Sep;10(3):282-91.

 

Diagnosing a myelodysplastic syndrome (MDS) can be challenging. Somatic mutations are common in MDS and might have diagnostic utility in patients with idiopathic cytopenias of undetermined significance (ICUS). However, using mutations to diagnose MDS is complicated by several issues: ...

Last Updated: 31 Aug 2015

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome

 

Last Updated: 12 Apr 2016

Go to URL
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
 

Status: Recruiting

Condition Summary: Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic Syndrome

 

Last Updated: 26 Apr 2016

Go to URL
Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
 

Status: Recruiting

Condition Summary: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia

 

Last Updated: 3 Jun 2016

Go to URL